Navigation Links
Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call
Date:5/2/2013

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:Isis Pharmaceuticals' First Quarter 2013 Financial Results and Highlights Conference CallWhen:Tuesday, May 7, 2013 at 4:30 p.m. ET / 1:30 p.m. PTWhere:www.isispharm.com How:Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
2. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
3. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
4. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
5. Henry Schein To Webcast First Quarter 2013 Conference Call On Tuesday, May 7 At 10:00 a.m. ET
6. Thoratec Schedules First Quarter Conference Call, Webcast
7. Volcano Corporation Schedules First Quarter Conference Call, Webcast
8. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
9. Amgen Announces Webcast of 2013 First Quarter Financial Results
10. HeartWare Schedules First Quarter Conference Call And Webcast
11. Regeneron to Report First Quarter 2013 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Patient Monitoring Equipment ... monitor physiological signs. These devices are either used as ... monitoring is one of the key factors for the ... market. Hence, vendors are developing technologically advanced products that ... send test results on time and provide better patient ...
(Date:2/21/2017)... Feb. 21, 2017 Micro Guide Catheters ... http://www.reportlinker.com/p04711314-summary/view-report.html Micro Guide Catheters ... hospitals, specialty clinics and ambulatory surgery centers etc. ... tip. The selection of micro guide catheter depends ... in human body. Micro guide catheters are available ...
(Date:2/21/2017)... IBM ) Research has today announced new research developments ... retina. The Melbourne based IBM researchers ... in retina images, which could in the future offer doctors ... who may be at risk of eye diseases – such ... world. The research began in 2015 and ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its ... Dr. Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission ... premise liability and other personal injury cases. These injuries have a major impact ...
(Date:2/22/2017)... ... February 22, 2017 , ... The ... today, as organizations, advocates, and individuals join together to increase recognition about the ... ultimately save lives. , “Today we mark a nationwide movement to raise awareness ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
(Date:2/22/2017)... ... February 22, 2017 , ... The SeniorCare Investor will ... Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording of the ... of the Interactive Webinar Series. , If you want to find out what really ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is ... combat-related PTSD. , Established in 1977, our organization was at the forefront in ... returning to civilian life were evident and served as the catalyst for the ...
Breaking Medicine News(10 mins):